Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18207395 | 0.93 | TLR9 (0.51) | MEN1KMT2ANUDT1TLR7TLR9 | |
| SCHEMBL18207328 | 0.92 | USP28 (0.48) | TLR7TLR9 | |
| SCHEMBL18207490 | 0.88 | MEN1 (0.47) | MEN1KMT2ANUDT1TLR7ADORA2A | |
| SCHEMBL18207366 | 0.87 | TLR7 (0.55) | TLR7TLR9 | |
| SCHEMBL18207564 | 0.86 | KMT2A (0.46) | MEN1KMT2ANUDT1TLR7TLR9 | |
| SCHEMBL19924572 | 0.86 | TLR7 (0.47) | MEN1KMT2ANUDT1TLR7 | |
| SCHEMBL18207376 | 0.84 | MEN1 (0.52) | MEN1KMT2ATLR7 | |
| SCHEMBL18207310 | 0.84 | TLR7 (0.65) | NUDT1TLR7 | |
| SCHEMBL18207474 | 0.83 | TLR7 (0.46) | MEN1KMT2ANUDT1TLR7TLR9 | |
| SCHEMBL18207663 | 0.83 | TLR7 (0.46) | MEN1KMT2ANUDT1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | disclosed |
| CN-107580596-B | Sulfimidoylpurine ketone compounds and derivatives for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2020-07-14 | — | — | CN | disclosed |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3294740-B1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-3294740-B1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3294740-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2018-03-21 | — | — | EP | disclosed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9708325-B2 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708325-B2 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016180695-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180695-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-17 | — | — | WO | disclosed |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | MEN1 1471/4885KMT2A 2703/4885NUDT1 746/4885 |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | MEN1 1471/4885KMT2A 2703/4885NUDT1 746/4885 |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | NQO1, UGT1A1, SULT1E1 | MEN1 963/4885KMT2A 2133/4885NUDT1 71/4885 |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | NQO1, UGT1A1, SULT1E1 | MEN1 963/4885KMT2A 2133/4885NUDT1 71/4885 |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | STS, SULT1E1, SULT1A1 | MEN1 619/4885KMT2A 1875/4885NUDT1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.